Biophoton Therapy for Chronic Pain: Clinical and Real-World Breakthrough

Authors

  • James Z Liu First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA Author
  • Mariola A Smotrys First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA Author
  • Seth D Robinson Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Hui X Yu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Sherry X Liu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Devin R Liu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Helen Y Gu First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA Author

DOI:

https://doi.org/10.47363/tawsyn25

Keywords:

Biophoton Therapy, Chronic Pain, Tesla BioHealing, Non-Invasive Treatment, Live Blood Analysis, Opioid Alternative

Abstract

Background: Chronic pain presents a major clinical and public health challenge, particularly among patients with neurological and inflammatory diseases. Current pharmacological treatments often carry risks of side effects or dependency, highlighting the urgent need for safe, effective, non-invasive alternatives.

Objective: To evaluate the safety and efficacy of Tesla BioHealing® Biophoton Generators in reducing chronic pain, based on data from clinical trials and real-world users.

Methods: A total of 194 patients diagnosed with chronic conditions, including Parkinson’s disease, chronic stroke, traumatic brain injury, post-COVID syndrome, Alzheimer’s disease, and Lyme disease, participated in seven clinical trials conducted from 2020 to 2025. Pain levels were assessed using the SF-36 survey before and after 4 weeks of biophoton exposure. Additionally, real-world outcomes from over 45,000 users were analyzed via post-marketing surveys and testimonials. Ancillary studies included infrared thermography, meridian energy mapping, and dark-field microscopy of live blood samples.

Results: No adverse events were reported. Among 87 participants with moderate to severe baseline pain, only 21 remained symptomatic after 4 weeks, a 76% reduction. A randomized, triple-blinded, placebo-controlled trial on arthritis confirmed statistically significant pain relief in the biophoton group (p<0.01). Real-world users with severe pain reported average pain score reductions from 9.52 to 5.26. Infrared imaging showed reduced inflammation, meridian analysis revealed increased bioenergy circulation, and live blood microscopy confirmed restored fluidity and reduced oxidative stress.

Conclusion: Tesla BioHealing® Biophoton Generators provide a novel, drug-free therapy for chronic pain with strong safety and efficacy signals across diverse conditions. This technology offers a promising alternative to opioid-based therapies and supports broader applications in integrative neurology and pain medicine.

Author Biographies

  • James Z Liu, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

    First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

  • Mariola A Smotrys, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

    First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

  • Seth D Robinson, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Hui X Yu, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Sherry X Liu, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Devin R Liu, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Helen Y Gu, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

    First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

Downloads

Published

2025-09-01

Issue

Vol. 7 No. 9 (2025): Volume 7 Issue 9

Section

Articles